Atara Biotherapeutics Resubmits Tabelecleucel BLA to U.S. FDA

Key Facts

1Atara Biotherapeutics announced that its partner, Pierre Fabre Pharmaceuticals, has resubmitted the Biologics License Application (BLA) for tabelecleucel to the U.S. FDA.

Atara Biotherapeutics announced that its partner, Pierre Fabre Pharmaceuticals, has resubmitted the Biologics License Application (BLA) for tabelecleucel to the U.S. FDA. Business Wire reported that the resubmission follows previous regulatory interactions and marks a critical step toward securing approval for the immunotherapy targeting EBV-related diseases.

ATRA closed at $8.05 on September 29, 2026, having reached a session high of $8.82 and a low of $7.89 during that day's trading. The resubmission represents a significant milestone in the partnership between Atara and Pierre Fabre Pharmaceuticals as they seek to bring the treatment to the U.S. market.